(05.01.2020, 11:39)Boy Plunger schrieb: Erste Übertreibungen sehen wir im US-Biotechbereich.
Anbei eine ganz hilfreiche Übersicht aus einem Seeking Alpha Artikel über Pharma / Biotech-Werte und FDA Entscheidungen, die in diesem Jahr ihre Kurse beeinflussen könnten:
Zitat: 2020 is shaping up as a big year for drug announcements. Bernstein thinks the FDA's call on whether to approve an experimental Alzheimer's drug treatment called aducanumab from Biogen (NASDAQ:BIIB) will be the most important decision of the year. Leading off the FDA docket, Durect (NASDAQ:DRRX) is expected to hear during an AdCom meeting this month if Posimir lands approval as a post-surgical analgesia indication and there is a FDA review action due on Aimmune Therapeutics (NASDAQ:AIMT) peanut allergy treatment Palforzia. Other companies expecting key FDA rulings of varying natures later in the year include Acceleron Pharma (NASDAQ:XLRN) for Luspatercept, IntelGenx Technologies (NASDAQ: IGXT) on Rizaport for the treatment of acute migraines, Intercept Pharmaceuticals (NASDAQ:ICPT) obeticholic acid, Celgene (NASDAQ:CELG) on Ozanimod for multiple sclerosis, Vertex Pharmaceuticals (NASDAQ:VRTX) on a triple therapy to treat cystic fibrosis, Seattle Genetics (NASDAQ:SGEN) on Enfortumab for urothelial cancer, Merck (NYSE:MRK) on Ebola vaccine V920, NewLink Genetics (NASDAQ:NLNK) on Ebola vaccine V920, Bristol-Myers Squibb (NYSE:BMY) on Opdivo, Novo Nordisk (NYSE:NVO) on Ozempic and Rybelsus, Eli Lilly (NYSE:LLY) on a triple combination tablet for adults with Type 2 Diabetes, Blueprint Medicines (NASDAQ:BPMC) on Avapritinib, Global Blood Therapeutics (NASDAQ:GBT) on Voxelotor for the treatment of sickle cell disease and Alnylam Pharmaceuticals (NASDAQ:ALNY) on Givosiran.
